Cellular raw materials are an important determinant of effective cell therapy technology development and an especially key factor for clinical translation and the manufacturing scale-up of cell therapies. The Red Cross can streamline cell and gene therapy development through refined donor selection, cGMP production capabilities and standardized quality management approach.
The Red Cross is your partner in identifying donor selection criteria upfront that yield consistent, high quality starting materials to support successful process development, clinical manufacturing, and eventual commercialization of your unique cell therapies. We make available standard resources such as donor samples paired with pre- and post-collection donor questionnaires to enable valuable donor selection early on in your key raw materials sourcing, thereby driving efficiency in your processes.
Cell handling, processing and cryopreservation of raw materials, when necessary, are critical to the successful development and manufacturing of cell therapies. The Red Cross furthers our commitment to providing high-quality starting materials by offering GMP grade production of our processed, cryopreserved raw materials for use in the research and development stage through clinical trials and eventual commercial manufacturing of your advanced therapies.
By operating under a single Quality Management System and utilizing standard apheresis collection procedures, the Red Cross further limits the variability in starting materials and ensures consistency and reliability throughout our network.